Bloomberg Bloomberg Getty Images
Health and Human Services Secretary Alex Azar said there may be a substantial amount of Kovid-19 vaccines for every American in early March in the US on Thursday, a more optimistic estimate than President Donald Trump has publicly stated.
The Trump administration’s coronavirus vaccine program Operation War Speed is expected to have 100 million doses by the end of the year, Azar said during a keynote speech at the Goldman Sachs Healthcare virtual event on coronovirus. “That’s enough to cover a particularly vulnerable population,” he said.
“We have enough for every American who wants a vaccine from March to April 2021,” he said.
Due to the epidemic, US health officials are accelerating the development of vaccine candidates by investing in multiple stages of research, although doing so may be for naught if the vaccine is not effective or safe.
Azar said the US is currently manufacturing supplements for all six potential vaccines supported by the US government in more than 23 manufacturing facilities. This includes vaccines from Modern, Pfizer, AstraZeneca and Johnson & Johnson, all of which are under late trial. He said that the US is also receiving needles, syringes, bottles and other supplies needed for vaccination.
He postponed the US government’s partnership with medical supplies company McKesson, which was hired as the main distributor of Kovid-19 vaccines.
“We are extremely pleased with our success so far,” he said.
Trump repeatedly stressed that the vaccine could be authorized for emergency use in early October because by April there is a sufficient vaccine dose for every American.
Azar said Thursday that US health officials believe that authorizing the vaccine for emergency use is appropriate “only in specific circumstances” where “there are sufficient quantities of vaccines already manufactured.”
The Centers for Disease Control and Prevention outlined a comprehensive plan to make Kovid-19 vaccines available to all Americans free of charge last month. In the plan, the CDC stated that it anticipated that the coronovirus vaccine would initially be granted an emergency use authority before full formal approval.
CDC Director Dr. Robert Redfield said that plenty of guidance, but not all of those described in the plan, would overlap with the many routine activities for vaccination and pandemic influenza planning.
When large quantities of the vaccine become available, the CDC said, there will be two simultaneous objectives: to provide wider access to vaccination and to ensure higher growth in the target population, particularly those who are prone to death or complications from Kovid-19 Are at high risk.
Azar’s remarks come as infectious pathologists and scientists fear that the Kovid-19 vaccine will be delivered before being adequately tested.
Earlier this week, the Food and Drug Administration set updated safety standards for Kovid-19 vaccine manufacturers. The standards, posted in a document on the FDA’s website, would almost certainly prevent a vaccine from being released before the presidential election on November 3.
The standards have been shared with pharmaceutical companies, who are trying to reduce the apprehension that vaccine development is proceeding very rapidly to ensure this. He issued a joint statement in September, stating that “stand with the science” rather than politics says clinical trials will not sacrifice the safety or effectiveness of a vaccine.